- ART enables greater workflow efficiency and lean sample
management, supporting laboratories' path towards total
automation
- The Procleix Panther System featuring ART improves system
usability, increases operator walk-away time, and allows
laboratories to select efficient configurations suitable for
current or future blood donor screening automation needs
- The Grifols ART program is a cross-platform,
long-term research and development initiative to enable ongoing
advancements in laboratory workflow optimization
BARCELONA, Spain, Oct. 17, 2019 /PRNewswire/ -- Grifols (MCE: GRF)
(MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of
plasma-derived medicines and a leader in the development of
innovative diagnostic solutions, today announced that it has
obtained the CE mark for the Procleix Panther System featuring
ART.
Built on the success of the Procleix Panther System, ART
technology features significant hardware and software improvements
that support blood-banking operations of all sizes, such as
instrument networkability and information sharing.
ART supports laboratory efforts to reach complete sample
automation. It offers increased control over workflow and personnel
utilization, from standard processes to the more complex. It also
enables the connection of as many as 16 instruments to a track
system for automated sample handling.
The Procleix Panther System featuring ART is expected to
reinforce the company's leadership in this market segment. It will
be available in all markets accepting CE-mark after completion of
any additional registration/notification requirement, while
registration for other markets is currently underway.
"The CE mark represents another pivotal moment in our company's
commitment to partner with blood banks worldwide to improve the
safety of donated blood and workflow optimization in the light of
increasing workloads and personnel shortages," said Carsten Schroeder, President and CEO, Grifols
Diagnostic Solutions Inc. "As part of our mission to improve
patient well-being and blood safety worldwide, we continue to
innovate via efficient, versatile, and user-focused solutions."
About the Procleix Panther System
The Procleix Panther System automates all aspects of NAT
(Nucleic Acid Technology)-based blood screening on a single,
integrated platform, and is capable of delivering the highest
result throughput per square meter. It eliminates the need for
batch processing and combines walk-away freedom with intuitive
design for ease of use.
ART technology enhancements further increase the system's
versatility, offering customizable options and more on-demand
features to fit the evolving needs and budgets of blood banks
worldwide.
About Procleix NAT Solutions
Today, Procleix systems are used to screen more blood donations
around the world than any other NAT blood screening products, and
include tests for HIV, Hepatitis viruses (A, B, C and E), West Nile
virus, Zika virus, Dengue virus, Babesia, and more.
About Grifols
Grifols is a global healthcare company founded in Barcelona in 1909, committed to improving the
health and well-being of people around the world. Its four
divisions - Bioscience, Diagnostic, Hospital and Bio Supplies -
develop, produce and market innovative solutions and services in
more than 100 countries.
As pioneers in the field of plasma science, Grifols is one of
the largest plasma companies, with a growing network of donation
centers worldwide. It develops this plasma into essential medicines
used to treat rare, chronic and, at times, life-threatening
conditions. As a recognized leader in transfusion medicine, Grifols
also offers a comprehensive portfolio of solutions designed to
enhance safety from donation through transfusion. In addition, the
company supplies tools, information and services that enable
hospitals, pharmacies and healthcare professionals to efficiently
deliver expert medical care.
Grifols, with more than 22,000 employees in 30 countries, is
committed to a sustainable business model that sets the standard
for continuous innovation, quality, safety and ethical leadership
in the industry.
The company's class A shares are listed on the Spanish Stock
Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols
non-voting class B shares are listed on the Mercado Continuo
(MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).
For more information, visit grifols.com.
Product registration and availability vary by
country.
Procleix is a registered trademark of Grifols
Worldwide Operations Limited.
Panther is a registered
trademark of Hologic, Inc.
Logo -
https://mma.prnewswire.com/media/847347/Grifols_Logo.jpg